Tralhão J G, Kayal S, Dagher I, Sanhueza M, Vons C, Franco D
Service de Chirurgie Géndérale, H6pital Antoine Béclère, Facultd de Médecine Paris XI, France.
Hepatogastroenterology. 2007 Jun;54(76):1200-6.
BACKGROUND/AIMS: Certain prognostic factors affect the postoperative mortality and long-term survival of patients following hepatic resection for hepatocellular carcinoma (HCC) and may change the surgical strategy.
209 consecutive patients underwent hepatic resection for HCC in our hospital. Seventy-three patients underwent major resection and 136 underwent minor resections. We looked for correlations between clinical, biological, surgical and pathological factors and postoperative mortality, disease-free survival and overall survival.
The postoperative mortality rate was 7.7% (it fell to 0% in the last two years). The cumulative overall five-year survival rate was 27% and the overall disease-free survival rate was 7.3%. Multivariate analysis identified: (1) two independent prognostic factors for postoperative mortality: age and tumor size; (2) one risk factor for tumor recurrence: intraoperative blood transfusion, and (3) three independent prognostic factors for overall survival: infiltrative tumor type, surgical margin <10 mm and intraoperative blood transfusion.
In addition to routine staging of the tumor, the preoperative evaluation of HCC patients should include tests to determine whether the tumor is infiltrative or expansive and whether it will be possible to obtain a surgical margin (>10 mm). This procedure should make it possible to propose an appropriate neoadjuvant treatment only to these patients. The prevention of intraoperative bleeding or blood transfusion should improve the disease-free and overall survival rates in HCC patients.
背景/目的:某些预后因素会影响肝细胞癌(HCC)肝切除术后患者的死亡率和长期生存率,并可能改变手术策略。
我院209例连续接受HCC肝切除术的患者。73例行大手术切除,136例行小手术切除。我们探寻临床、生物学、手术和病理因素与术后死亡率、无病生存率和总生存率之间的相关性。
术后死亡率为7.7%(最近两年降至0%)。累积总五年生存率为27%,总无病生存率为7.3%。多因素分析确定:(1)术后死亡的两个独立预后因素:年龄和肿瘤大小;(2)肿瘤复发的一个危险因素:术中输血,以及(3)总生存的三个独立预后因素:浸润性肿瘤类型、手术切缘<10mm和术中输血。
除了常规的肿瘤分期外,HCC患者的术前评估应包括检测以确定肿瘤是浸润性还是膨胀性的,以及是否有可能获得手术切缘(>10mm)。这一程序应仅能为这些患者提出合适的新辅助治疗方案。预防术中出血或输血应能提高HCC患者的无病生存率和总生存率。